Research and Markets: The Diabetes Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/439e09/the_diabetes_marke) has
announced the addition of the "The Diabetes Market Outlook To 2014: Market
Dynamics, Competitive Landscape, Emerging Therapies" report to their offering.

Diabetes mellitus is a chronic metabolic disorder that results due to a failure
of the body to produce the hormone insulin and/or an inability of the body to
respond adequately to circulating insulin. Type 1 diabetes, previously referred
to as insulin-dependent diabetes mellitus (IDDM), occurs most commonly in
children or young adults and constitutes 5-10% of the diagnosed diabetes patient
population. Type 2 diabetes, previously known as adult-onset diabetes or
non-insulin-dependent diabetes mellitus (NIDDM), accounts for 90-95% of
diagnosed diabetes cases globally and typically develops in middle-aged adults.
The 2008 prevalence of diabetes mellitus, together in the seven major markets,
was 8.5% with Germany having the highest prevalence rate at 11.8%. But the
disease has been growing at epidemic proportions, a fact that has driven
extensive R&D in this therapy area.

The global diabetes market was worth $27.3bn in 2008 and was led by insulin
analogs which captured 45.0% of the market followed by glitazones that captured
a share of 22.8%. US is the largest diabetes market globally with sales of
$12.9b in 2008 and a market share of 47.6%. However the highest growth in sales
y-o-y was exhibited by several early emerging economies such as UAE at 59.7%.

Scope of this report:

* Epidemiological analysis of the therapy area and forecast prevalence over the
period 2009-14 .
* Forecasts and analysis of the key products in the diabetes market over the
period 2009-14 spread across the major classes of treatments.
* Overview of key events in the global diabetes market that have impacted
treatment trends and sales potential.
* Strategic and growth analysis of leading pharmaceutical corporations based on
sales focus by drug class, currently marketed products and R&D product
portfolios.

Key findings from this report:

* Biguanides, mainly comprised of metformin, are the core first line therapy in
diabetes care. These drugs have been used in diabetes therapy for over a decade.
Some of their advantages include, efficacy, low cost, extensive experience, lack
of incidences of hypoglycemia and weight neutrality. Metformin lost patent
protection in 2002 and the class is now much genericized and has been ceding
market share to other therapies.
* Insulin captured the largest market share (45%) among available diabetes
treatments and is likely to dominate the market in the forecast period. However,
though insulin analogs have become well established in the market, inhaled
insulin is yet to make its mark.
* Significant R&D has been observed in the pre-insulin market leading to the
development of several novel and safer therapies. The comparative performance of
these therapies, such as the DPP-IV inhibitors and GLP-1 analogs would shape the
diabetes market landscape through 2014 and in the long term.

Key issues:

* Revised FDA guidelines make the regulatory environment challenging In December
2008, the FDA announced that the companies developing diabetes drugs will be
required to conduct longer and larger studies to avoid any "unacceptable"
cardiovascular risk. Companies are now required to conduct meta analyses for
cardiovascular safety in the Phase II and III trials and rule out the
possibility of an increased cardiovascular disease risk by 80% or more.
* Inhaled insulin still a distant reality Insulin therapy takes up the biggest
share of diabetes treatment and has been an area of extensive research. While
several different purer forms of insulin have emerged over a period of time,
nasally administered insulin is still a distant reality. Inhaled insulin may aid
compliance, leading to superior long term outcomes. Pfizer/Nektar's Exubera was
the first to be launched inhaled insulin but it had a troubled launch and was
subsequently discontinued in October 2007. The only inhaled insulin which is
still under development is Technosphere, being developed by Mannkind/Afresa.
This insulin uses a technology that facilitates absorption of proteins and
peptides through the pulmonary route.

Use this report to:

* Which companies were the leading players in the diabetes therapy area in 2008?

* How have recent major launches from the key market players performed?
* Which companies will become the key players in the diabetes market over the
period 2009-14?
* Which products will be impacted by generic competitors over the period
2009-14?

Companies Mentioned:

* Boehringer Ingelheim
* Eli Lilly
* GSK
* Merck & Co.
* Novo Nordisk
* Sanofi-aventis and Takeda

For more information visit
http://www.researchandmarkets.com/research/439e09/the_diabetes_marke

Source: Business Insights

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2009